Journal
MOUNT SINAI JOURNAL OF MEDICINE
Volume 78, Issue 2, Pages 207-220Publisher
WILEY-BLACKWELL
DOI: 10.1002/msj.20249
Keywords
cytokines; multiple sclerosis; multiple sclerosis therapies; neuroinflammation
Categories
Funding
- TEVA pharmaceuticals
- Bayer Health
- Serono
- Biogen/Idec
Ask authors/readers for more resources
Multiple sclerosis is an inflammatory and degenerative disease of the central nervous system characterized by demyelination and axonal loss. Genetic and environmental factors contribute to the risk of immune dysregulation in multiple sclerosis. The review focuses on the immunopathogenic role played by various lymphocyte subsets and their cytokine products in the onset and disease progression, and the role of regulatory immune cells in disease remission. The mechanism of action of approved and experimental therapies, and how these mechanisms support the immunopathogenesis paradigm, is also reviewed. Mt Sinai J Med 78:207-220, 2011. (C) 2011 Mount Sinai School of Medicine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available